Search results
Oct 30, 2024 · Pre-AIA 35 U.S.C. 103 Conditions for patentability; nonobvious subject matter. (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to ...
- 2122-Discussion of Utility in The Prior Art
2164.01-Test of Enablement. 2164.01(a)-Undue Experimentation...
- 2143-Examples of Basic Requirements of a Prima Facie Case of Obviousness
The question of whether a claimed invention can be shown to...
- 2103-Patent Examination Process
Examiners must first determine the scope of a claim by...
- 2120-Rejection on Prior Art
35 U.S.C. 103 Conditions for patentability; non-obvious...
- 2190-Prosecution Laches and Res Judicata
Manual of Patent Examining Procedure. 2190 Prosecution...
- 2158-Aia 35 U.S.C. 103
¶ 7.20.aia Statement of Statutory Basis, 35 U.S.C. 103. The...
- 2165-The Best Mode Requirement
2165 The Best Mode Requirement [R-08.2017] I. REQUIREMENT...
- 2106-Patent Subject Matter Eligibility
2106.04 Eligibility Step 2A: Whether a Claim is Directed to...
- 2122-Discussion of Utility in The Prior Art
Oct 30, 2024 · The question of whether a claimed invention can be shown to be obvious based on an “obvious to try” line of reasoning has been explored extensively by the Federal Circuit in several cases since the KSR decision. The case law in this area is developing quickly in the chemical arts, although the rationale has been applied in other art areas as well.
This Note traces the history of the obvious-to-try test and analyzes its current status, particularly with respect to the pharmaceutical arts. Part I begins by introducing the significance of the nonobviousness patentability requirement in the pharmaceutical arts, including the function of the obvious-to-try test.
Oct 30, 2024 · The ultimate determination of patentability is based on the entire record, by a preponderance of evidence, with due consideration to the persuasiveness of any arguments and any evidence properly made of record. In re Oetiker, 977 F.2d 1443, 24 USPQ2d 1443 (Fed. Cir. 1992). The legal standard of “a preponderance of evidence” requires the ...
May 24, 2022 · The MPEP sets forth the following requirements for an "obvious to try"-type rejection: a finding that at the time of the invention, there had been a recognized problem or need in the art, which ...
Aug 22, 2023 · This Note discusses important considerations for determining whether a reference document or activity qualifies as prior art and the potential patentability and validity in Canada of a claimed invention over the prior art. It also addresses novelty and non-obviousness in connection with both patentability and validity evaluations.
People also ask
Is “obvious to try” a valid patentability test?
How is patentability determined?
Does the “obvious to try” test affect the patentability of pharmaceutical inventions?
Is the obvious-to-try patentability test inappropriate in the pharmaceutical arts?
How do you decide if a patent is patentable?
Does discovery of a problem always result in a patentable invention?
Jul 23, 2015 · An invention may be “obvious to try” if there are a finite number of possible routes that could be used to solve the problem. An invention that can only be reached when a skilled person makes a series of correct decisions is likely not self-evident or “obvious to try”. Level of effort required.
